Subscribe

DOI: 10.4244/EIJ-D-18-00542L

Indexed patent ductus arteriosus size as the prime predictor of post device closure left ventricular dysfunction: does it have any competitors?

Naveen Garg, MD, DM; Krishnarpan Chatterjee*, MD, DNB

In their study, Kiran et al propose the indexed patent ductus arteriosus (PDA) size at the pulmonary artery end as a simple predictor of post-procedural left ventricular (LV) dysfunction in those with baseline normal LV function1. Whilst we agree with the authors’ observation that the size of the PDA is an important prognostic marker, it is not uncommon to find a PDA where the diameter at the pulmonary artery end is not the minimum diameter. In such cases, the minimum PDA diameter indexed to body surface area may be an appropriate measure. Although this is by far the largest published group and a commendable effort, we believe that methodological gaps prevent this study from establishing the indexed PDA size as a more robust predictor.

The authors consider a univariate model and show a significant correlation between indexed PDA size and post-procedural LV dysfunction. We are curious to know whether this would stand up as an independent predictor in a multivariate model. Previous studies have been limited by their small sample size but have made some important observations. Gupta et al showed that baseline LV ejection fraction, LV end-diastolic volume and PDA diastolic gradient predicted post-procedural LV dysfunction2. Jeong et al showed that device closure should be carried out before left ventricular ejection fraction (LVEF) decreases to less than 62% in order to have a normal post-closure EF3. Pre-closure global longitudinal strain (GLS) predicted LV dysfunction measured as increased myocardial performance index (MPI)4. A larger left to right shunt and higher pulmonary artery pressure pre-closure is also associated with LV dysfunction estimated by fractional shortening5. Both LVEF and MPI are load-dependent measures of LV function. During “afterload mismatch” in the immediate post-closure period, isovolumic acceleration (IVA) would be a better measure of LV function. Age at the time of procedure is also a plausible predictor of LV dysfunction2.

Including all these variables along with indexed PDA size in a multivariate model would allow us to extract maximum inference from the large study population in this article. Distribution of the baseline variables across the four pre-specified groups should also be made available.

We hope that our suggestions would help in interpreting the study data further and possibly generate further new hypotheses.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Volume 14 Number 18
Apr 5, 2019
Volume 14 Number 18
View full issue


Key metrics

Suggested by Cory

CLINICAL RESEARCH

10.4244/EIJ-D-15-00238 Apr 20, 2017
Are the AMPLATZER Duct Occluder II Additional Sizes devices dedicated only for smaller children?
Fiszer R et al
free

Clinical research

10.4244/EIJ-D-23-00517 Dec 18, 2023
Changes in post-PCI physiology based on anatomical vessel location: a DEFINE PCI substudy
Matsumura M et al
free

10.4244/EIJ-D-21-00445L Sep 20, 2021
Letter: When is the optimal time point for detecting malapposition in coronary bifurcation trials?
Holck E and Andreasen L
free
Trending articles
310.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
172.05

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
76.25

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
35

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
Chat with Cory
Hello , I'm Cory and I will do my best to answer your questions about this article. Please remember that this is an experimental feature, and that I'm still learning.
What measure of PDA size did the study propose?
What alternative measure does the letter suggest?
What other factors have previous studies found predict post-closure dysfunction?
How do LVEF and MPI compare as measures of LV function?
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved